A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

NCT05006716 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

614

Enrollment

INDUSTRY

Sponsor class

Conditions

B-cell Malignancy
Marginal Zone Lymphoma
Follicular Lymphoma
Non-Hodgkin Lymphoma
Waldenström Macroglobulinemia
Chronic Lymphocytic Leukemia
Small Lymphocytic Lymphoma
Mantle Cell Lymphoma
Diffuse Large B Cell Lymphoma

Interventions

DRUG: BGB-16673

Sponsor

BeOne Medicines